Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 116 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Gastroesophageal (GE) Junction Carcinomas - Pipeline Review, H2 2014', provides an overview of the Gastroesophageal (GE) Junction Carcinomas's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroesophageal (GE) Junction Carcinomas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gastroesophageal (GE) Junction Carcinomas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gastroesophageal (GE) Junction Carcinomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroesophageal (GE) Junction Carcinomas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroesophageal (GE) Junction Carcinomas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroesophageal (GE) Junction Carcinomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gastroesophageal (GE) Junction Carcinomas Overview 8
Therapeutics Development 9
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Overview 9
Pipeline Products for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis 10
Gastroesophageal (GE) Junction Carcinomas - Therapeutics under Development by Companies 11
Gastroesophageal (GE) Junction Carcinomas - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Gastroesophageal (GE) Junction Carcinomas - Products under Development by Companies 16
Gastroesophageal (GE) Junction Carcinomas - Companies Involved in Therapeutics Development 17
Amgen Inc. 17
Aslan Pharmaceuticals Pte. Ltd. 18
AstraZeneca PLC 19
Basilea Pharmaceutica AG 20
Bristol-Myers Squibb Company 21
Celltrion, Inc. 22
F. Hoffmann-La Roche Ltd. 23
Gilead Sciences, Inc. 24
Merck & Co., Inc. 25
Merck KGaA 26
Merrimack Pharmaceuticals, Inc. 27
Novartis AG 28
Ono Pharmaceutical Co., Ltd. 29
Taiho Pharmaceutical Co., Ltd. 30
Zymeworks Inc. 31
Gastroesophageal (GE) Junction Carcinomas - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(tegafur + gimeracil + oteracil) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
alpelisib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
BAL-101553 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
DKN-01 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
gefitinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GS-5745 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ipilimumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
luminespib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MK-2206 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MM-111 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MSB-0010718C - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
nimotuzumab - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
nivolumab (recombinant) - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
pertuzumab - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SNX-5422 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
trastuzumab biosimilar - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
trebananib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
varlitinib - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
ZW-9 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Gastroesophageal (GE) Junction Carcinomas - Recent Pipeline Updates 88
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects 112
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products 113
Gastroesophageal (GE) Junction Carcinomas - Product Development Milestones 114
Featured News & Press Releases 114
Sep 19, 2014: Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on MM-111 at the ESMO 2014 Congress 114
Feb 06, 2012: Aslan Pharma Receives KFDA And IRB Grants Approval To Initiate Phase IIa Study Of ASLAN001 At Seoul National University 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 116
Disclaimer 116

List of Tables
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H2 2014 9
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H2 2014 17
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 18
Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H2 2014 19
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H2 2014 20
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H2 2014 21
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H2 2014 22
Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Gilead Sciences, Inc., H2 2014 24
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H2 2014 25
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H2 2014 26
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 27
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Novartis AG, H2 2014 28
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 29
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2014 30
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Zymeworks Inc., H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Assessment by Combination Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 41
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H2 2014 88
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H2 2014 112
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H2 2014 113